Teva Announces AZILECT® (Rasagiline Tablets) Data To Be Presented At The 16th Annual International Congress Of Parkinson’s Disease And Movement Disorders

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced that data from studies of AZILECT ^® (rasagiline tablets) and Parkinson’s disease (PD) will be featured at the 16 ^th Annual International Congress of Parkinson’s Disease and Movement Disorders in Dublin, Ireland, 17-21 June 2012.

More than fifteen abstracts will highlight data from ongoing and completed studies of PD and AZILECT ^®, a MAO-B inhibitor for the treatment of PD, in the areas of pre-clinical, clinical and health economics research.

“We are proud of the variety of topics and quality of research results that will be presented at MDS this year,” said Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer, Teva Pharmaceutical Industries Ltd. “We are committed to ongoing collaboration with academia, medical institutions and patient advocacy groups to continue our understanding of the role AZILECT ^® may play in the treatment landscape for the PD community – patients, their families and friends, and healthcare professionals.”

Presentations include:

Ongoing studies assessing effects of AZILECT ^® treatment on motor and non-motor PD symptoms, both as monotherapy and when added to ongoing dopamine agonist therapy:

• [345] Evaluating the Efficacy of Rasagiline on Depressive Symptoms and Cognition in Parkinson’s Disease Patients without Dementia: the ACCORDO Study (Session PD Clinical Trials: 18 June 2012 at 12:45 PM IST) Paolo Barone for the ACCORDO Study Investigators, Salerno, Italy
• [374] A Placebo-controlled, Randomized, Multicenter Study of Rasagiline as Add-on Therapy to Dopamine Agonists for Treatment of Early Parkinson’s Disease: the ANDANTE Study (Session PD Clinical Trials: 18 June 2012 at 12:45 PM IST) Robert Hauser, Tampa, FL,USA; Azhar Choudhry, Kansas City, MO, U.S.

New clinical trial results:

• [450] A Comparative Study on Safety and Tolerability of Rasagiline Versus Pramipexole in Early Parkinson’s Disease: the ACTOR Study (Session PD Clinical Trials: 18 June 2012 at 12:45 PM IST) Francois Viallet, Provence, France, Severine Pitel, Marseille, France, Sylvie Lancrenon, Bourg la Reine, France, Oliver Blin, Marseille, France

ABOUT AZILECT ^®

AZILECT ^® tablets (rasagiline tablets) are indicated for the treatment of the signs and symptoms of Parkinson's disease both as initial therapy alone and to be added to levodopa later in the disease in patients with end-of-dose fluctuations

Patients should not take AZILECT ^® if they are taking meperidine, tramadol, methadone, propoxyphene, dextromethorphan, St. John’s wort, cyclobenzaprine, or other monoamine oxidase inhibitors (MAOIs), as it could result in a serious reaction. Patients should inform their physician if they are taking, or planning to take, any prescription or over-the-counter drugs, especially antidepressants and ciprofloxacin. Patients with moderate to severe liver disease should not take AZILECT ^®. Patients should not exceed a dose of 1 mg per day of AZILECT ^® in order to prevent a possibly dangerous increase in blood pressure.

Side effects seen with AZILECT ^® alone are flu syndrome, joint pain, depression, and indigestion; and when taken with levodopa are uncontrolled movements (dyskinesia), accidental injury, weight loss, low blood pressure when standing, vomiting, anorexia, joint pain, abdominal pain, nausea, constipation, dry mouth, rash, abnormal dreams, and fall.

See additional important information at http://www.azilect.com/Resources/PDFs/PrescribingInformation-pdf.aspx. For hardcopy releases, please see enclosed full prescribing information.

AZILECT ^® is currently available in more than 40 countries worldwide, including the U.S., Canada, Israel, Mexico, and all EU countries. Teva has a long-term agreement for the joint development and marketing of AZILECT ^® in Europe and some additional markets with H. Lundbeck A/S. In North America, AZILECT ^® is marketed by Teva's wholly-owned subsidiary, Teva Neuroscience, Inc. ( www.tevaneuro.com).

ABOUT TEVA

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $18.3 billion in net revenues in 2011.

1 2 3 Next › Last »